Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER versus PARACAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER versus PARACAINE.
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER vs PARACAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also has antiarrhythmic properties by decreasing automaticity in Purkinje fibers and suppressing ventricular arrhythmias.
Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.
Intrathecal administration for spinal anesthesia: 50-100 mg (1.5-2 mL of 5% solution) as a single dose. For continuous epidural or peripheral nerve block, 0.8% solution with dextrose 5% is not typically used; refer to 1-2% lidocaine without dextrose for continuous infusion.
10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.
None Documented
None Documented
Clinical Note
moderateProparacaine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."
Clinical Note
moderateProparacaine + Clemastine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."
Clinical Note
moderateProparacaine + Venlafaxine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."
Clinical Note
moderateTerminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 5-8 hours) or hepatic impairment (up to 10-15 hours). Clinically, context indicates redistribution half-life ~8 minutes.
2.5 hours; prolonged to 8 hours in cirrhosis due to reduced hepatic metabolism
Renal (metabolites: 4-hydroxyxylidine, glycylxylidide, monoethylglycinexylidide; <10% unchanged). Biliary/fecal negligible.
Renal: 90% (70% unchanged, 20% as paracainol glucuronide); Biliary/Fecal: 10%
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic
Proparacaine + Nefazodone
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Nefazodone."